GPCRs regulate cellular responses to neurotransmitters and hormones and act as ligand-regulated guanosine nucleotide exchange factors (GEFs) for heterotrimeric G proteins 1 . Ligand efficacy has historically referred to the capacity of a molecule to elicit a specific physiological response downstream of receptor activation 2, 3 . Although an important parameter in drug development, the molecular basis of efficacy with respect to the effect of a ligand on GPCR structure, dynamics and G-protein coupling remains poorly understood.
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β 2 AR, a paradigmatic, class A GPCR, couples preferentially to the heterotrimeric G s protein, consisting of Gα s , Gβ and Gγ (Fig. 1a ) 4 . Investigations of the β 2 AR activation mechanism have been enabled by synthetic ligands with efficacy profiles ranging from inverse agonists that suppress basal activity, and neutral antagonists that prevent agonist-induced activation, to partial and full agonists that differentially promote receptor-mediated G s activation 5 . Recent crystallographic structures of distinct class A GPCRs in both inactive and active states [6] [7] [8] [9] revealed that the largest conformational change associated with their activation is an outward movement of the cytoplasmic end of TM6 (ref. 6 ). In the nucleotide-free β 2 AR-G s complex, TM6 is stabilized in an outward configuration by insertion of the C-terminal α 5 helix of Gα s into a pocket formed by the cytoplasmic ends of TM3, TM5 and TM6 and intracellular loop 2 (ICL2).
Ensemble techniques, including fluorescence 10 , electron paramagnetic resonance (EPR) 11 and nuclear magnetic resonance (NMR) spectroscopy 11, 12 reveal that even the most potent agonists fail to fully stabilize β 2 AR in its activated conformation in the absence of G protein Within the GDP-free complex the α 5 helix (red) of Gα s (wheat) engages or stabilizing nanobodies. The molecular basis of ligand efficacy may therefore be defined by changes in receptor dynamics and conformation that impact the probability of G-protein coupling, productive nucleotide exchange and subsequent dissociation. Hence, we used total internal reflection fluorescence (TIRF) single-molecule fluorescence resonance energy transfer (smFRET) imaging to track TM6 movements in β 2 AR bound to ligands with distinct efficacy profiles to determine the effects on receptor structure, dynamics, and G-protein coupling.
Site-specific labelling of β 2 AR
We site-specifically attached donor and acceptor fluorescent probes at the cytoplasmic ends of TM6 (L266C 6.28 ) and TM4 (N148C 4.40 ), respectively, within a full-length, minimal cysteine β 2 AR mutant (Fig. 1a , Supplementary Methods). This construct (β 2 Δ 6-148C/266C) exhibits wild-type ligand binding and G s coupling (Extended Data Fig. 1a-c) .
Given the relatively small size of β 2 AR (~ 34 Å lateral dimension) and the anticipated displacement of TM6 (~ 14 Å) upon activation 6 ( Fig. 1a) , β 2 Δ 6-148C/266C was labelled with an optimized Cy3B and Cy7 fluorophore pair (Cy3B* and Cy7* ; Extended Data Figs 2a, b and 3a, b, Supplementary Methods), which exhibit high quantum yields and a small R 0 value (~ 50.7 Å) (Extended Data Fig. 2a -e) and should be relatively insensitive to chemical environment 13 . Labelled receptors showed wild-type activities with respect to both antagonist and agonist binding (Extended Data Fig. 1a, b) .
Ligand-induced TM6 displacement
The effects of saturating concentrations of nine ligands with distinct efficacies (Fig. 1b, Extended Data Fig. 1d , e) were examined by imaging Cy3B* /Cy7* -labelled β 2 Δ 6-148C/266C immobilized with an M1 Fab fragment (Fig. 2a, b, Extended Data Figs 3c and 4a, b) . In the presence of the neutral antagonist alprenolol, and the inverse agonists carazolol and ICI-118,151 (ICI), β 2 AR exhibited indistinguishable population FRET efficiencies centred at 0.74 ± 0.01 (mean of biological replicates ± s.d.) and full-width at half-maximum height (FWHM) values of 0.1 ± 0.01 (Fig. 2b) . Inspection of individual trajectories from alprenolol-, carazolol-and ICI-bound receptors revealed relatively stable fluorescence and FRET (Extended Data Fig. 4a ). Similar results were obtained when β 2 AR was immobilized via biotinylated alprenolol (Extended Data Fig. 3d, e) . These data predict an average inter-dye distance of approximately 42 Å (Extended Data Fig. 2d-f ), in good agreement with molecular dynamics simulations (Extended Data Fig. 5a, b) .
The unliganded (apo) β 2 AR exhibited mean FRET and FWHM values similar to that of alprenolol, carazolol and ICI (Fig. 2b) . In the presence of the partial agonists clenbuterol, salmeterol or salbutamol, β 2 AR exhibited modestly lower, and more broadly distributed FRET values (0.70-0.72; FWHM = 0.15) (Fig. 2b) . Reductions in FRET were more pronounced in the presence of the full agonists adrenaline, isoproterenol and BI-167107, where the mean FRET value shifted to approximately 0.64 (FWHM = 0.15) (Fig. 2b) . In agreement with radioligand-binding studies (Extended Data Fig. 1e) , smFRET experiments showed that adrenaline exhibited a half-maximum effective concentration (EC 50 ) of 0.48 ± 0.09 μ M (mean of biological replicates ± s.e.m.) (Fig. 2c, Extended Data Fig. 3f ). Hence, we infer that these adrenaline-induced FRET changes (Δ FRET apo/adrenaline = 0.1), corresponding to an increase in average inter-dye distance of approxi mately 4 Å (Extended Data Fig. 2e ), reflect those of a fully functional receptor.
While the approximate 14 Å outward TM6 movement observed in fully activated β 2 AR ( ), reversible TM6 movements. By this measure, more rapid TM6 dynamics (more negative mean correlation) were observed in agonist-bound samples than antagonist-bound samples (Fig. 2e, f) . Simulations revealed that the observed fluorescence correlation and FRET distributions could be recapitulated by TM6 deflections to lower FRET states at rates of 100-500 s −1 (Extended Data Fig. 4d , e). Previous reports of slower TM6 movements (~ 0.5-5.0 s −1 ) 11,16 may reflect differences in experimental conditions or the nature of their probes, which detect changes in environment, not distance. Hence, we conclude that the distinct FRET values observed for each agonist reflect differences in the underlying rates and/or amplitudes of TM6 motions into, and out of, active-like conformations, which are time-averaged at the present imaging resolution.
The rate of β 2 AR-G s complex formation
To ascertain directly the extent to which the ligand-induced changes observed in smFRET correlate with the coupling efficiency of β 2 AR to G protein, labelled β 2 AR (1 nM) was incubated with G s (8 μ M) and apyrase (0.2 nM). Individual β 2 AR molecules were subsequently imaged via M1 immobilization to determine the extent of β 2 AR-G s complex formation (Fig. 3a) .
In the presence of carazolol and ICI, β 2 AR exhibited FRET behaviours that were indistinguishable from those observed in the Article reSeArcH absence of the G s heterotrimer (Figs 2b, 3b) . By contrast, agonistactivated β 2 AR complexes exhibited a distinct low-FRET (~ 0.4) state with similar FWHM values (~ 0.14) (Fig. 3b) . This low-FRET value reflects an inter-dye distance of approximately 55 Å (Extended Data Fig. 2e ), in close agreement with molecular dynamics simulations of the β 2 AR-G s complex (Extended Data Fig. 5a-c) . Analogous low-FRET states were observed when agonist-activated receptor was immobilized via a biotinylated G s heterotrimer (Extended Data Fig. 6a-d) . The proportion of receptors exhibiting low FRET values (Fig. 3b) , as well as the fraction of time that individual receptors occupied low-FRET states (Extended Data Fig. 7a ), correlated with ligand efficacy (Fig. 1b) . Consistent with the known basal activity of β 2 AR 17 , low levels (5-20%) of G s coupling were evidenced in the absence of ligand and in the presence of alprenolol (Fig. 3b, Extended Data Fig. 7a) .
To examine the role of ligand efficacy on the rates of β 2 AR-G s complex formation, M1-immobilized β 2 AR (Fig. 3c) was imaged in the presence of 30 μ M GDP at increasing G s concentrations, where reversible transitions between high-and low-FRET states could be quantified using a two-state hidden Markov Model (Fig. 3d , Supplementary Methods). Consistent with a bimolecular reaction entailing at least one ligand-dependent, rate-determining process that precedes complete G s coupling, we found that rates of low-FRET state formation increased with G s concentration and then plateaued (Fig. 3e , Extended Data Table 1 ).
On the basis of the initial slope of the G s -dependent increase in the rate of low-FRET state formation, we estimate the apparent G s on rate to β 2 AR at around 0.03 and 0.05 μ M −1 s −1 for clenbuterol and adrenaline, respectively (Fig. 3e , Extended Data Table 1 ). These rates are orders of magnitude slower than expected for the binding of large entities 18 . They are, however, similar to bioluminescence resonance energy transfer measurements of β 2 AR-mediated G s activation in living cells (2-3 s
, in which G s lipidation localizes the heterotrimer to cellular membranes. They are also consistent with the observation that rate-limiting conformational changes within the rhodopsin-G t complex precede GTP loading, although G t activation occurs at a faster rate 20 . Hence, either initial interactions between G s and β 2 AR preceding low-FRET state formation are highly transient (< < 100 ms) or do not immediately precipitate a FRET change. We therefore hypothesized that G s coupling may be rate-limited by one or more ligand-dependent conformational processes that occur within a high-FRET β 2 AR-G s complex.
Ligand effects on β 2 AR-G s stability
To examine the stability of apyrase-treated β 2 AR-G s complexes in the presence of partial and full agonists, we measured the dissociation rate of β 2 AR from immobilized G s heterotrimers (Extended Data Fig. 6a ). Under low illumination intensity, where photobleaching was negligible, immobilized β 2 AR-G s complexes exhibited lifetimes of 5-10 min (Extended Data Table 2 ). Notably, these lifetimes decreased by around 20-100 fold in the presence of physiological concentrations of GDP (30 μ M) or GTP (100 μ M) 21 (Extended Data Table 2 ), to become similar to those observed in cell-based studies of β 2 AR-G s 19 and β 1 AR-G s complexes 22 . Hence, β 2 AR-G s complexes generally persist for multiple seconds in the presence of nucleotide and dissociate approximately twofold faster in the presence of GTP compared to GDP. These observations are consistent with specific interactions between the receptor and nucleotide-bound G protein and suggest nucleotide-specific dissociation pathways.
To track changes in FRET efficiency within the nucleotide-depleted β 2 AR-G s complex upon GDP or GTP nucleotide binding, we performed analogous experiments at high spatial and temporal resolution (Fig. 4 , Extended Data Fig. 6a , e, f). In contrast to the relatively slow rates of complex dissociation, the rapid introduction (100 ms mixing time) of either GDP (30 μ M) or GTP (100 μ M) gave rise to an immediate increase, or broadening, of the low-FRET state (Δ FRET ≈ 0.05-0.10) (Fig. 4 , Extended Data Fig. 6e , f). These data indicate that nucleotides bind the nucleotide-free β 2 AR-G s complex at, or near, the diffusion limit, and that binding results in structural and/or dynamic changes in TM6 that initiate its return towards the helix bundle. Notably, these rapid changes were followed by the formation of a relatively long-lived, predominantly high-FRET configuration from which reversible transitions to lower-FRET states occurred with frequencies and durations that were efficacy dependent (Fig. 4 , Extended Data Fig. 6e, f) .
The addition of GTP triggered transitions to high-FRET that were more rapid and complete than observed for GDP, and both the rate and efficiency of high-FRET state formation were greater for full agonists than for partial agonists (Fig. 4b, d , Extended Data Fig. 6f ). These findings provide direct evidence for nucleotide-specific dissociation pathways, and suggest that β 2 AR-G s (GNP) complexes can access multiple conformations distinct from the nucleotide-free state observed crystallographically 6 . The observed persistence of high-FRET, GDP-and GTP-loaded configurations indicates the existence of relatively long-lived, β 2 AR-G s (GDP) complexes during initial binding that precede low-FRET state formation, as well as long-lived β 2 AR-G s (GTP) complexes after G-protein activation. While the absolute rates we observe may be influenced by interactions between the lipid modifications on G s and the detergent micelle surrounding β 2 AR, pre-and post-coupled GEF-G-protein complexes have been observed in distinct systems using independent methods [23] [24] [25] [26] and may have important consequences for GPCR signalling.
Ligand effect on G-protein activation
The effect of ligand efficacy on the allosteric link between β 2 AR and G s , and its role in nucleotide exchange was further examined in steadystate experiments using M1-immobilized receptor in the presence of activating ligands, nucleotide and 8μ M G s (Fig. 5a, Extended Data  Fig. 7b, c) . Under such conditions, G s dissociation events are expected to be slow (around 0.1-0.2 s −1 ; Extended Data Table 2 ), while dynamic processes within the β 2 AR-G s complex should occur rapidly (Fig. 4) . As noted above, β 2 AR-G s complexes can exhibit three distinct FRET states: (1) a low-FRET, nucleotide-free state (0.4); (2) a high-FRET, agonist-bound (0.64) or partial agonist-bound (0.72) state while the receptor remains associated with G s ; and (3) an intermediate-FRET state (approximately 0.5) reflecting a GDP-bound β 2 AR-G s complex with a distinct mode of interaction between TM6 and the α 5-helix that is relatively short lived (Fig. 4c) . Because the two lower-FRET states can be seen clearly only in pre-steady-state experiments, we analysed our steady-state data as a two-state system in which states (1) and (3) are collapsed into a single, broadly defined (0.4-0.5) low-FRET state.
To learn about the rate-limiting features of β 2 AR-G s complex formation, we examined the rates of low-and high-FRET state formation (k high→low and k low→high , respectively) over a range of GDP concentrations. As expected for binding of a GDP-bound G s heterotrimer, k high→low was largely independent of GDP concentration for all agonists (Extended Data Fig. 8a ). By contrast, k low→high increased with GDP and plateaued at concentrations above 20 μ M (Fig. 5a) . Consistent with TM6 dynamics occurring within the β 2 AR-G s complex, the maximum rates exiting low FRET were approximately 5-15-fold more rapid than the apparent G s dissociation rate (Extended Data Table 2 ). The rank order of the low-to high-FRET state transition was: clenbuterol, salbutamol, salmeterol, BI-167107, isoproterenol and adrenaline. Given that GDP binding to the nucleotide-free β 2 AR-G s complex is rapid (Fig. 4a, c, Extended Data Fig. 6e ), we conclude that the transition out of low-FRET states into high-FRET states is rate-limited by one or more ligand-dependent processes within the β 2 AR-G s (GDP) complex.
As low FRET includes both nucleotide-free and GDP-bound complexes (Fig. 4a, c) , we speculated that the slower rates of return to high FRET observed for full agonists (Fig. 5a ) may reflect higher proportions of the relatively stable nucleotide-free state. We therefore undertook an evaluation of differences in the proportion of nucleotide-free β 2 AR-G s complexes in the presence of distinct agonists using the experimentally observed mean value of the low-FRET state as a function of GDP concentration (Fig. 5b, c) . This analysis revealed that the low-FRET state values observed at saturating GDP concentration (100 μ M) were considerably lower for full agonists compared to partial agonists, more closely approximating the FRET value (~ 0.4) observed for the nucleotide-free β 2 AR-G s complex (Extended Data Fig. 8c, d ). Consistent with GDP binding promoting a return to the high-FRET state, increasing GDP concentrations increased the mean values of the low-FRET states, while decreasing their time-averaged occupancies (Fig. 5b, c) . The concentration dependence of these effects revealed that full agonists exhibited EC 50 values that were approximately 2-3-fold higher than for partial agonists (Fig. 5d, Extended Data Fig. 8e ). These data suggest that β 2 AR-G s complexes exhibit higher affinity for GDP when bound to partial agonists than when bound to full agonists. They also support the notion that low-FRET states represent a mixture of nucleotide-free and GDP-bound β 2 AR-G s configurations, where complexes activated by full agonists spend more time on average in the relatively stable, nucleotide-free state. These findings may help to explain why adrenaline promotes a greater extent of [ 3 H]GDP release from β 2 AR compared to salbutamol 27 , despite both agonists promoting low-FRET states at similar rates (Fig. 3e) . As the rates of GDP binding to nucleotide-free β 2 AR-G s complexes are rapid, and appear indistinguishable at the present time resolution (Fig. 4a, c) , we conclude that more efficacious agonists increase the probability of GDP release and thus the likelihood that nucleotide-free states are achieved.
To test this model directly, we performed analogous GTP titrations in the presence of a fixed, saturating GDP concentration (30 μ M) (Extended Data Fig. 7b, c) . As anticipated, the transition rate from low-to-high FRET (k low→high ) was in all cases specifically increased at even the lowest GTP concentrations tested (100 nM) (Fig. 5e, Extended  Data Fig. 8b ). While the absolute values of k low→high were greater for partial agonists in the presence of GTP (Fig. 5e) , the fold increase in rate, and hence the magnitude reduction in low-FRET state lifetime, correlated with ligand efficacy in the order: adrenaline, isoproterenol, BI-167107, salmeterol, salbutamol and clenbuterol (Fig. 5e, f, Extended  Data Fig. 8h ). Taken together with the rapid rates of GDP and GTP binding to nucleotide-free β 2 AR-G s complexes (Fig. 4) , we conclude that the relatively short-lived, active-like, low-FRET β 2 AR conformations observed in the presence of partial agonists (Fig. 5a , e, f) predominantly reflect failed attempts at nucleotide release, and that full agonists more efficiently promote relatively long-lived, nucleotide-free configurations (Extended Data Fig. 8f, g ). Hence, ligands with greater efficacy preferentially promote GDP release, and under competitive conditions, rapid and efficient GTP loading to the subpopulation of nucleotide-free complexes. The more rapid return of β 2 AR-G s (GTP) complexes to high-FRET states after GTP loading argues that the terminal phosphate of GTP lowers the barrier for the rate-limiting conformational transition that enables the return of TM6 to its position adjacent to the helix bundle. This distinction may reflect GTP-specific effects on G s heterotrimer stability.
Discussion
We have examined ligand-activated G s binding, nucleotide exchange and G s release, from the perspective of time-dependent changes in β 2 AR conformation. The results illuminate the established concept of ligand efficacy in terms of a specific kinetic framework for the activation pathway (Fig. 6a) . Quantifying the ligand-dependence of both the rate and the efficiency of G s coupling in the presence of physiological GDP concentrations revealed that the process is achieved by rate-limiting conformational processes intrinsic to the β 2 AR-G s complex (Fig. 3e) . Although the nature of the interactions preceding excursions to low-FRET, active-like conformations are not presently known, the rates evidenced at saturating G s concentration (Fig. 3e) suggest ligand-specific effects on the probability that Gα s productively engages the intracellular face of β 2 AR after the complex has formed (Fig. 6a) . The molecular events underpinning these early activation steps minimally include the remodelling of the β 6α 5 loop proximal to the Gα s switch regions, and translation and rotation of the α 5 helix of G α away from the GDP binding pocket towards the intracellular vestibule in β 2 AR created by the outward movement of TM6 (Fig. 6b ) [28] [29] [30] [31] [32] [33] [34] [35] . The apparent differences in initial engagement and the ratelimiting conformational changes leading to active-like, lower-FRET states (Fig. 3e , Extended Data Table 1 ), provide an estimate of the relative ligand-dependent efficiencies (η 1 ) in these hidden early steps (Supplementary Methods). A second determinant of ligand efficacy (η 2 )-which probably arises from differences in how efficiently the α 5 helix C terminus of Gα s productively engages, and forms stabilizing interactions, with the intracellular β 2 AR surface 34 -can be estimated from the propensity of full agonists to more effectively promote GDP release (Supplementary Methods). Using the normalized parameters (η 1 , η 2 ), the efficacies of activating ligands relative to adrenaline (ε) can be ranked in terms of their effective rates of generating G s (GTP) from G s (GDP) (Fig. 6c, Supplementary Methods) . In doing so, we estimate that isoproterenol is around eight times more efficacious than clenbuterol. While these predictions suggest greater efficacy differences than inferred from in vitro GTP turnover assays (Fig. 1b) , they are in close agreement with cyclic AMP production in living cells (Fig. 6d) . Ligand-specific disparities in our calculated values versus the measured ligand efficacy values may reflect agonist-specific differences in GTP binding rates and/or affinities, which could not be accurately quantified.
In addition to providing quantitative insights into ligand efficacy, the present smFRET studies shed light on β 2 AR-G s conformations that are structurally distinct from the nucleotide-free complex (Fig. 1a) . While GDP-and GTP-bound complexes may be too unstable for crystallographic study, in-depth characterizations of these states are expected to provide important insights into both G-protein coupling rates and specificities. Quantitative single-molecule imaging investigations will be crucial in such efforts, as well as for delineating distinct liganddependent GPCR signalling pathways.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper.
Data Availability
The data that support the findings of this study are available from the corresponding authors upon reasonable request. 
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Extended Data Figure 3 | smFRET experimental controls. a, Site-specific labelling. SDS-PAGE gels under green (540 nm) or near infrared (740 nm) illumination for fluorescence visualization of Cy3B* or Cy7* labelling of β 2 Δ 6 and β 2 Δ 6-148C/266C. Coomassie-stained gel image is shown as a gel-loading control. Digestion with factor Xa protease and deglycosylation with PNGase F leads to separation of the 148C and 266C labelling sites on generated N-terminal and C-terminal fragments, respectively. For gel source data, see Supplementary Fig. 1 . b, Quantification of Cy3B* /Cy7* -labelling specificity of full-length β 2 Δ 6-148C/266C. Data are normalized to β 2 Δ 6-148C/266C labelling. c, Specificity of streptavidin-mediated receptor immobilization. Frame capture from immobilization movies showing labelled β 2 Δ 6-148C/266C on streptavidin-free (− SA) or streptavidin-coated (+ SA) surfaces. Bar graph shows the number of immobilized, labelled β 2 AR in these conditions. Error bars represent the s.d. from two replicates. d, Schematic of labelled β 2 AR immobilization via biotinylated alprenolol (alp-biotin). e, FRET population contour plot and histogram for alp-biotin-immobilized receptor shows correspondence with the FRET population distribution of biotin-M1-Fab-immobilized, alprenolol-bound, labelled β 2 AR (Fig. 2b) . Histogram error bars represent the s.d. from four replicates, with n total molecules analysed. f, FRET population contour plots (top) and histograms (bottom) for adrenaline titration on biotin-M1-Fab-immobilized, labelled β 2 Δ 6-148C/266C (Fig. 2c) (Fig. 5a) or GTP in the presence of saturating GDP (30 μ M) (Fig. 5e) , with n indicating the total number of molecules analysed from two replicates. Nucleotide-free (0 μ M GDP; from Fig. 3b ) and ligand-only (from Fig. 2b ) conditions are included as references. Scale bar on the right indicates the relative population for the contour plots. (Fig. 5f ) is shown for different agonists. All error bars represent s.d. from two replicates.
